ASIF 13th General Council Meeting

Guangzhou, China
10-13 October 2018

The ASIF Council meeting will take place in China this year, kindly hosted by Dr Gu and the Association of Chinese AS Patients and Medical Advisory Board of Chinese Health Promotion Foundation.

The meeting is from 10-13 October. The programme is still being finalised but will in part focus on raising awareness.

Speakers will include:

Dr Muhammad Asim Khan, MD, FRCP, MACP, MACR an expert in research into spondyloarthropaies.  Dr Khan is a founding member of ASAS, SPARTAN and GRAPPA

Jennifer Visscher from Walk AS One, a very successful online campaigner

Souzi Makri, President ENFA, EUPATI Fellow, Vice-President CYPLAR, Honorary Chair AGORA.  Souzi will talk about personalised treatment and shared decision-making

Dr Tuncay Duruöz will talk about the new criteria for axial and peripheral spondyloarthritis.

We really want to hear from our members at this meeting so there will be plenty of opportunity for you to take part in workshops and we will invite each country attending to give a short presentation about something of note – a recent success story or triumph – or even something that did not go so well. So that we can all learn from each other.

We hope to have presentations from up to 8 new member counties.

There will be a welcome dinner on Wednesday 10 October, Thursday, Friday and Saturday morning will be talks and workshops. On Saturday afternoon our hosts are planning and excellent trip out for us to see some points of interest.

We will be staying at the Guangzhou Southern Congress 1 Station Hotel. I will send out more details along with invitations and registration booking forms in February.

For those who want to get ahead booking their flights, the nearest airport is Guangzhou Baiyun International Airport.

We really hope that as many of you will come to the meeting in China as possible.

Other NEWS

Intimacy and AS

Michael Mallinson has lived with AS for over 35 years. He developed this content as a consultant to Novartis Ph

Read More
UCB’s CIMZIA© approved for potential use in women with AS during breastfeeding and pregnancy

The European Medicines Agency (EMA) has approved the label change for UCB's CIMZIA© (certolizumab pegol), making i

Read More

ASIF 13th General Council Meeting

Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.Lorem ipsum dolor sitamet consect adipiscine elit. Vestibulum elemen at magna ut interdum praesent volutpat lectus ac viverra.

Other NEWS

Intimacy and AS

Michael Mallinson has lived with AS for over 35 years. He developed this content as a consultant to Novartis Ph

Read More
UCB’s CIMZIA© approved for potential use in women with AS during breastfeeding and pregnancy

The European Medicines Agency (EMA) has approved the label change for UCB's CIMZIA© (certolizumab pegol), making i

Read More